Mediwound (MDWD) Lowered to “Sell” at Zacks Investment Research
Mediwound (NASDAQ:MDWD) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report issued on Thursday.
According to Zacks, “MediWound Ltd. is a biotechnology niche specialty company. It is focused on developing, manufacturing and commercializing products that address unmet needs in the fields of severe burn and chronic wound management. The company is also developing NexoBrid for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns. MediWound Ltd. is headquartered in Yavne, Israel. “
Other research analysts have also issued reports about the stock. Jefferies Group reissued a “buy” rating and set a $10.00 target price on shares of Mediwound in a research note on Thursday, September 28th. Oppenheimer set a $10.00 target price on shares of Mediwound and gave the company a “buy” rating in a research note on Thursday, November 16th. ValuEngine lowered shares of Mediwound from a “sell” rating to a “strong sell” rating in a research note on Friday, September 22nd. Cowen assumed coverage on shares of Mediwound in a research note on Thursday, September 28th. They set an “outperform” rating and a $9.00 target price for the company. Finally, SunTrust Banks set a $9.00 target price on shares of Mediwound and gave the company a “buy” rating in a research note on Thursday, November 16th. Two research analysts have rated the stock with a sell rating and five have issued a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus price target of $9.13.
Mediwound (NASDAQ:MDWD) last posted its earnings results on Thursday, November 16th. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.03. Mediwound had a negative net margin of 904.26% and a negative return on equity of 246.58%. research analysts anticipate that Mediwound will post -1.06 EPS for the current year.
Several hedge funds have recently added to or reduced their stakes in MDWD. Alyeska Investment Group L.P. bought a new stake in shares of Mediwound during the 3rd quarter worth about $2,140,000. Migdal Insurance & Financial Holdings Ltd. raised its position in shares of Mediwound by 20.3% during the 2nd quarter. Migdal Insurance & Financial Holdings Ltd. now owns 2,028,112 shares of the biopharmaceutical company’s stock worth $13,791,000 after buying an additional 342,165 shares in the last quarter. Nationwide Fund Advisors bought a new stake in shares of Mediwound during the 3rd quarter worth about $1,538,000. Finally, Wells Fargo & Company MN raised its position in shares of Mediwound by 23.5% during the 2nd quarter. Wells Fargo & Company MN now owns 65,763 shares of the biopharmaceutical company’s stock worth $447,000 after buying an additional 12,522 shares in the last quarter. Institutional investors own 29.46% of the company’s stock.
MediWound Ltd. is a biopharmaceutical company. The Company focuses on developing, manufacturing and commercializing therapeutics products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The Company’s product, NexoBrid, is indicated for the removal of dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns, also referred to as severe burns.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Mediwound Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mediwound and related companies with MarketBeat.com's FREE daily email newsletter.